BUPROPION HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Bupropion Hydrochloride, and what generic alternatives are available?
Bupropion Hydrochloride is a drug marketed by Accord Hlthcare, Actavis Labs Fl Inc, Anbison Lab, Anchen Pharms, Annora Pharma, Aurobindo Pharma Usa, Epic Pharma Llc, Granules, Graviti Pharms, Impax Labs, Invagen Pharms, Jubilant Generics, Lupin Ltd, Mylan, Prinston Inc, Sandoz, Sciegen Pharms Inc, Scinopharm Taiwan, Sinotherapeutics Inc, Sun Pharm, Torrent, Watson Labs Inc, Wockhardt Ltd, Yichang Humanwell, Zhejiang Jutai Pharm, Zydus Pharms, Alembic, Apnar Pharma Lp, Apotex Inc, Cadila Pharms Ltd, Heritage Pharma, Invatech, and Micro Labs. and is included in fifty-eight NDAs.
The generic ingredient in BUPROPION HYDROCHLORIDE is bupropion hydrochloride. There are thirty-eight drug master file entries for this compound. Seventy-five suppliers are listed for this compound. Additional details are available on the bupropion hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bupropion Hydrochloride
A generic version of BUPROPION HYDROCHLORIDE was approved as bupropion hydrochloride by APNAR PHARMA LP on February 7th, 2000.
Summary for BUPROPION HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 33 |
NDAs: | 58 |
Finished Product Suppliers / Packagers: | 71 |
Raw Ingredient (Bulk) Api Vendors: | 137 |
Clinical Trials: | 377 |
Patent Applications: | 1,205 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in BUPROPION HYDROCHLORIDE? | BUPROPION HYDROCHLORIDE excipients list |
DailyMed Link: | BUPROPION HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for BUPROPION HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Mclean Hospital | Phase 4 |
Kenya Medical Research Institute | Phase 4 |
Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude | Phase 2 |
Pharmacology for BUPROPION HYDROCHLORIDE
Drug Class | Aminoketone |
Mechanism of Action | Dopamine Uptake Inhibitors Norepinephrine Uptake Inhibitors |
Physiological Effect | Increased Dopamine Activity Increased Norepinephrine Activity |
Anatomical Therapeutic Chemical (ATC) Classes for BUPROPION HYDROCHLORIDE
Paragraph IV (Patent) Challenges for BUPROPION HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
FORFIVO XL | Extended-release Tablets | bupropion hydrochloride | 450 mg | 022497 | 1 | 2013-02-28 |
WELLBUTRIN XL | Extended-release Tablets | bupropion hydrochloride | 150 mg and 300 mg | 021515 | 1 | 2004-09-21 |